Bullous Pemphigoid Insights and Trends

• Bullous pemphigoid shows a rising global cases trend over recent decades, largely attributed to population aging, improved diagnostic recognition, and increased exposure to triggering medications such as diuretics and immune checkpoint inhibitors.
• Seasonal variation pattern in incidence is observed, with higher diagnosis rates reported in warmer months in several European areas, suggesting possible environmental or infection-related triggering mechanisms.
• Bullous pemphigoid is increasingly recognized as part of a broader autoimmune clustering phenomenon, with patients showing higher-than-expected co-occurrence of other autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, autoimmune thyroid disease), suggesting shared immune dysregulation pathways. 
• Bullous pemphigoid is most common in older females, age 70 and older. It’s not as common in males, younger adults, and children

Bullous Pemphigoid Epidemiology Forecast in the 7MM

• 2025 Prevalent Cases of Bullous Pemphigoid : ~XX
• 2036 Projected Prevalent Cases of Bullous Pemphigoid : ~XX
• Bullous Pemphigoid Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Bullous Pemphigoid Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the bullous pemphigoid, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Bullous Pemphigoid Understanding and Diagnosis Algorithm

Bullous Pemphigoid Overview and Diagnosis

Bullous pemphigoid is a chronic autoimmune subepidermal blistering disorder caused by an immune response against structural proteins of the skin basement membrane, primarily BP180 (type XVII collagen) and BP230. Autoantibody-mediated immune activation leads to complement activation, eosinophilic inflammation, and tissue damage, resulting in the formation of tense blisters. The disease primarily affects the elderly population and is associated with significant morbidity, impaired quality of life, recurrent disease episodes, and treatment-related complications. Clinical manifestations commonly include severe pruritus, urticarial or eczematous lesions, and tense fluid-filled blisters, although atypical non-bullous presentations may delay diagnosis.

Diagnosis of bullous pemphigoid is based on a combination of clinical assessment, histopathology, and immunological testing. A skin biopsy typically demonstrates a subepidermal blister with eosinophil-rich inflammation, while direct immunofluorescence (DIF) of perilesional skin remains the gold standard diagnostic method, showing linear deposition of IgG and complement component C3 along the basement membrane zone. Serological detection of BP180 and BP230 autoantibodies using assays such as ELISA further supports diagnosis and disease monitoring. 

Further details are provided in the report.

Bullous Pemphigoid Epidemiology

Key Findings from Bullous Pemphigoid Epidemiological Analysis and Forecast 

• Bullous pemphigoid is the most common autoimmune subepidermal blistering disorder, representing 80% of subepidermal immunobullous cases. bullous pemphigoid most commonly affects elderly patients between the ages of 60–80 years.
• The overall prevalence of pemphigoid is 0.012%, or 12 pemphigoid patients/100,000 adults in the US.
• Bullous Pemphigoid had the highest prevalence of all Autoimmune Bullous Diseases, followed by pemphigus vulgaris, mucous membrane pemphigoid, and chronic bullous dermatosis of childhood.
• The disease is associated with a higher burden in elderly patients due to frequent comorbidities and chronic disease course. Patients with bullous pemphigoid often require prolonged treatment and monitoring because of disease relapses, persistent pruritus, and complications associated with both the disease and immunosuppressive therapies.
• Bullous pemphigoid increases significantly with advancing age, with the highest occurrence observed among individuals aged ≥80 years, highlighting the strong association between disease development and aging. 

Scope of the Report

• The report covers a segment of a descriptive overview of bullous pemphigoid, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Bullous Pemphigoid Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of bullous pemphigoid? What will be the growth opportunities across the 7MM concerning the patient population with bullous pemphigoid?
• What is the historical and forecasted bullous pemphigoid patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.